Victory Capital Management Inc. boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 82.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 539,782 shares of the biopharmaceutical company's stock after buying an additional 243,702 shares during the quarter. Victory Capital Management Inc. owned approximately 0.44% of Catalyst Pharmaceuticals worth $13,090,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the 4th quarter worth $29,000. Sound Income Strategies LLC acquired a new position in Catalyst Pharmaceuticals during the 1st quarter worth $64,000. GAMMA Investing LLC lifted its holdings in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 579 shares in the last quarter. Quarry LP acquired a new position in Catalyst Pharmaceuticals during the 4th quarter worth $104,000. Finally, New Vernon Capital Holdings II LLC acquired a new position in Catalyst Pharmaceuticals during the 4th quarter worth $122,000. Institutional investors and hedge funds own 79.22% of the company's stock.
Analyst Ratings Changes
Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of "Buy" and an average price target of $32.83.
Get Our Latest Analysis on CPRX
Catalyst Pharmaceuticals Price Performance
Shares of CPRX stock traded down $0.05 during trading hours on Friday, reaching $20.97. The company had a trading volume of 908,559 shares, compared to its average volume of 1,297,321. The company has a 50 day moving average of $22.96 and a 200 day moving average of $22.89. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 13.36, a P/E/G ratio of 0.85 and a beta of 0.66. Catalyst Pharmaceuticals, Inc. has a 1-year low of $15.34 and a 1-year high of $26.58.
Insiders Place Their Bets
In related news, insider Preethi Sundaram sold 2,324 shares of the company's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the completion of the sale, the insider owned 42,681 shares in the company, valued at $1,127,205.21. This represents a 5.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 200,000 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the completion of the sale, the insider owned 68,873 shares of the company's stock, valued at approximately $1,630,912.64. This represents a 74.38% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 247,924 shares of company stock worth $5,879,369. 10.40% of the stock is currently owned by company insiders.
Catalyst Pharmaceuticals Profile
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Further Reading

Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.